RSV Vaccine: Over-75s & Care Home Residents Eligible in England
In April, a broader range of individuals in England will become eligible for respiratory syncytial virus (RSV) vaccination. The expansion of the programme will offer the vaccine to adults aged 80 and over, as well as residents in care homes.
Expanding Protection Against RSV
This move builds upon existing eligibility, which already includes individuals aged 75 and over. The vaccination programme aims to reduce the impact of RSV, a common respiratory virus that can cause serious illness, particularly in vulnerable populations.
Significance of the Expansion
Offering the RSV vaccine to a wider age group and care home residents is a proactive step toward protecting those most at risk of severe complications from the virus. This expansion acknowledges the potential for RSV to cause significant health challenges for older adults.
What Could Happen Next
As the vaccination programme expands, public health officials may monitor its effectiveness in reducing RSV-related hospitalizations and severe illness. Further analysis of the programme’s impact could lead to adjustments in eligibility criteria or vaccination strategies in the future. It is also possible that ongoing research will inform recommendations regarding booster doses or vaccine formulations.
Frequently Asked Questions
Who is now eligible for the RSV vaccine in England?
Adults aged 80 and over, and all residents in care homes for older adults, will be eligible for the RSV vaccine from April 1, 2026. This is in addition to those already eligible aged 75 and over.
When will the expanded RSV vaccination programme begin?
The expanded programme will begin in April 2026.
What is the purpose of expanding RSV vaccine eligibility?
The expansion aims to protect older adults and care home residents from the serious illness that RSV can cause.
How might expanded access to the RSV vaccine impact the overall health of older adults in England?